clouddn.eureka.digital - /NN/NovoSeven Key Components/HQ22NS00006 Components_NovoSeven_PrintCVA/__MACOSX/HQ22NS00006_Reference Pack/
[To Parent Directory]
9/2/2022 9:41 AM 552 ._(Copyrights restricted)_Healthcare Improvement Scotland 2012 Sco_v1.0.pdf
9/2/2022 9:42 AM 552 ._(Copyrights restricted)_WHO 2012 WHO recommendations for the pre_v1.0.pdf
9/2/2022 9:39 AM 552 ._1. NovoSeven SmPC, 2018, eMC_v1.0.pdf
9/2/2022 9:30 AM 552 ._11. NovoSeven Approved Package Insert SA_v1.0.pdf
9/2/2022 9:32 AM 552 ._2. Rexen P et al. TH Open 2019 3e45_e492019_v2.0.pdf
9/2/2022 9:33 AM 552 ._3. Pollard et al., J Haem Pract 2017 4(1) 1_5._v1.0.pdf
9/2/2022 9:29 AM 552 ._35_ODEYEMI_2002_v1.0.pdf
9/2/2022 9:29 AM 552 ._36_Hart_2002_v1.0.pdf
9/2/2022 9:40 AM 552 ._A cost evaluation of treatment alternatives for mild-to-moderate_v1.0.pdf
9/2/2022 9:40 AM 552 ._Abshire T, Kenet G 2008 Safety update in the use of recombinanat_v1.0.pdf
9/2/2022 9:31 AM 552 ._Abshire T, Kenet G. Haemophilia 14(5)： 898-902, 2008_v1.0.pdf
9/2/2022 9:42 AM 552 ._ACOG Practice Guidelines. Clinical Management Guidelines for Obs_v1.0.pdf
9/2/2022 9:31 AM 552 ._Amano K et al.：Haemophilia 23（1）：50-58, 2016_v1.0.pdf
9/2/2022 9:32 AM 552 ._Assessment of in vivo administered recombinant activated factor_v1.0.pdf
9/2/2022 9:30 AM 552 ._Balkan C et al.：Haemophilia 16(6)：902-909, 2010_v1.0.pdf
9/2/2022 9:30 AM 552 ._Baudo F et al.： Blood 120(1)： 39-46, 2012_v1.0.pdf
9/2/2022 9:32 AM 552 ._Baudo F et al.：Blood 120（1）：39-46, 2012_v1.0.pdf
9/2/2022 9:40 AM 552 ._Bienstock et al. 2021 Postpartum Hemorrhage_v1.0.pdf
9/2/2022 9:30 AM 552 ._Boadas A et al.：Haemophilia 17(3)： 422-427, 2011_v1.0.pdf
9/2/2022 9:31 AM 552 ._Bolton-Maggs et al, 2006, Br J Haematol_v1.0.pdf
9/2/2022 9:30 AM 552 ._Borg JY et al.：Haemophilia 19（4）：564-570, 2013_v1.0.pdf
9/2/2022 9:32 AM 552 ._Borhany, 2012, Haemophilia_v1.0.pdf
9/2/2022 9:33 AM 552 ._Bowcutt et al. 2008 Implementation of an intravenous medication_v1.0.pdf
9/2/2022 9:31 AM 552 ._Bysted BV et al.： Haemophilia 13(5)： 527-532, 2007_v1.0.pdf
9/2/2022 9:41 AM 552 ._Carroli G et al. 2008 Epidemiology of postpartum haemorrhage a s_v1.0.pdf
9/2/2022 9:32 AM 552 ._Caviglia_2011_v1.0.pdf
9/2/2022 9:42 AM 552 ._Christopoulos P et al. 2011 Obstetric hysterectomy A review of c_v1.0.pdf
9/2/2022 9:29 AM 552 ._Chung_2004_v1.0.pdf
9/2/2022 9:40 AM 552 ._Collins PW et al.：BMC Res Notes 3 161, 2010_v1.0.pdf
9/2/2022 9:30 AM 552 ._Collins PW, et al., BMC Res Notes, 3：161, 2010_v1.0.pdf
9/2/2022 9:40 AM 552 ._Cost and effectiveness of treatments for mild-to-moderate bleedi_v1.0.pdf
9/2/2022 9:39 AM 552 ._Cost-effectiveness of recombinant porcine Factor VIII (OBIZUR) f_v2.0.pdf
9/2/2022 9:31 AM 552 ._Croom KF, McCormack PL. Biodrugs 22(2)：121-136, 2008_v1.0.pdf
9/2/2022 9:30 AM 552 ._de_Souza_2009_v2.0.pdf
9/2/2022 9:32 AM 552 ._Demartis F 2017 Real-World Early Treatment with Room Temperature_v1.0.pdf
9/2/2022 9:28 AM 552 ._Demartis F et al. 2017 Real-World Early Treatment with Room Temp_v1.0.pdf
9/2/2022 9:31 AM 552 ._Di Minno et al, 2015, Haematologica_v1.0.pdf
9/2/2022 9:29 AM 552 ._DUNDAR_2005_v1.0.pdf
9/2/2022 9:39 AM 552 ._Emicizumab Prophylaxis in Hemophilia A with Inhibitors_v1.0.pdf
9/2/2022 9:43 AM 552 ._EPAR 2022 NovoSeven II-116 CHMP extension of indication variatio_v1.0.pdf
9/2/2022 9:40 AM 552 ._Ericsson A, et al. 2012 Swedish Adaptation of Czech Pharmacoeco_v1.0.pdf
9/2/2022 9:29 AM 552 ._FDA Approves New Formulation of Coagulation Therapy NovoSeven RT_v1.0.pdf
9/2/2022 9:40 AM 552 ._Feiba PI (Competitor PI)_v2.0.pdf
9/2/2022 9:28 AM 552 ._FEIBA Summary of Product Characteristics_v1.0.pdf
9/2/2022 9:40 AM 552 ._Fernandez-Bello 2017 - The pharmacokinetics and pharmacodynamics_v1.0.pdf
9/2/2022 9:31 AM 552 ._Fernández-Bello I, et al. Haemophilia 2017;23(1)868–876._v1.0.pdf
9/2/2022 9:43 AM 552 ._GB OBIZUR Summary of Product Characteristics April 2022_v2.0.pdf
9/2/2022 9:32 AM 552 ._GB OBIZUR Summary of Product Characteristics July 2021_v1.0.pdf
9/2/2022 9:32 AM 552 ._Giangrande PL et al.： Haemophilia 15（2）：501-508, 2009_v1.0(1).pdf
9/2/2022 9:30 AM 552 ._Giangrande PL et al.： Haemophilia 15（2）：501-508, 2009_v1.0.pdf
9/2/2022 9:40 AM 552 ._Global causes of maternal death a WHO systematic analysis_v1.0.pdf
9/2/2022 9:30 AM 552 ._Goddard 2005 - Case studies orthopaedic surgery in adult patient_v1.0.pdf
9/2/2022 9:30 AM 552 ._Goudemand_2004_v2.0.pdf
9/2/2022 9:30 AM 552 ._Green D et al.：Thrombos Haemostas 46（3）：200-203, 1981_v1.0.pdf
9/2/2022 9:40 AM 552 ._Guidelines for Emergency Department Management of Individuals wi_v2.0.pdf
9/2/2022 9:43 AM 552 ._Hammami MB 2015 Partial Thromboplastin Time, Activated_v1.0.pdf
9/2/2022 9:31 AM 552 ._Hammami MB. Partial thromoplastin time, activated. Medscape_v1.0.pdf
9/2/2022 9:31 AM 552 ._Hay CR et al.：Thromb Haemost 7（8）：1463-1467, 1997_v1.0.pdf
9/2/2022 9:29 AM 552 ._Hay CRM, et al British Journal of Haematology 2000; 111 78-90_v1.0.pdf
9/2/2022 9:40 AM 552 ._Hedner U 2015 Recombinant activated factor VII 30 years of resea_v1.0.pdf
9/2/2022 9:28 AM 552 ._Hedner U. Blood Rev 29(S1： S4-S8, 2015pdf_v1.0.pdf
9/2/2022 9:40 AM 552 ._Hedner, 2015, Blood Reviews_v1.0.pdf
9/2/2022 9:28 AM 552 ._Hemlibra SmPC January 2021_v3.0.pdf
9/2/2022 9:40 AM 552 ._Hemlibra_SmPC_2018_v1.0.pdf
9/2/2022 9:32 AM 552 ._Hers, Mumford, 2008, Platelets_v1.0.pdf
9/2/2022 9:32 AM 552 ._Hoffman M, Monroe DM. Thromb Haemost 85（6）： 958-965, 2001_v1.0.pdf
9/2/2022 9:28 AM 552 ._Hoffman M, Thromb Haemost, 2001, 85, 958-965_Clean_v1.0.pdf
9/2/2022 9:29 AM 552 ._Huth-Kuehne_2006_v1.0.pdf
9/2/2022 9:30 AM 552 ._Huth-Kuhne A et al.：Haematologica 94（4）：566-575, 2009_v1.0.pdf
9/2/2022 9:30 AM 552 ._Ingerslev J et al.：Haemostasis 26（S1）： 118-123, 1996_v1.0.pdf
9/2/2022 9:31 AM 552 ._Jayakar JP, et al. 2018 Retrospective review of Acquired Haemoph_v1.0.pdf
9/2/2022 9:29 AM 552 ._Jimenez_2013_v1.0.pdf
9/2/2022 9:29 AM 552 ._Joshi_2006_v1.0.pdf
9/2/2022 9:28 AM 552 ._Jurlander B et al 2001 Recombinant Activated Factor VII (rFVIIa)_v1.0.pdf
9/2/2022 9:32 AM 552 ._Kjalke et al, 2001, Br J Haematol_v1.0.pdf
9/2/2022 9:41 AM 552 ._Knight M et al. 2021 Saving Lives, Improving Mothers’ Care - Le_v1.0.pdf
9/2/2022 9:31 AM 552 ._Knoebl P et al.：J Thromb Haemost 10（4）： 622-631, 2012_v1.0.pdf
9/2/2022 9:30 AM 552 ._Kruse-Jarres, et al. 2015. Haemophilia_v1.0.pdf
9/2/2022 9:42 AM 552 ._Lavigne-Lissalde 2015 Recombinant human FVIIa for reducing the n_v1.0.pdf
9/2/2022 9:33 AM 552 ._Lentz 2014_v1.0.pdf
9/2/2022 9:31 AM 552 ._Lentz SR et al 2014 A novel supplemental approach to capturing p_v1.0.pdf
9/2/2022 9:32 AM 552 ._Lentz SR et al.： J Thromb Haemost 12（8）：1244-1253, 2014_v1.0.pdf
9/2/2022 9:32 AM 552 ._Lisman et al, 2004, Blood_v1.0.pdf
9/2/2022 9:30 AM 552 ._Ma AD et al.：Blood Coagul Fibrinolysis 27（7）：753-60, 2016_v1.0.pdf
9/2/2022 9:31 AM 552 ._Ma AD et al.：Hematology Am Soc Hematol Educ Program ：432-437, 20_v1.0.pdf
9/2/2022 9:28 AM 552 ._Maahs J et al.： J Blood Med 5： 153-156, 2014_v1.0.pdf
9/2/2022 9:42 AM 552 ._Machado L. 2011 Emergency peripartum hysterectomy Incidence, ind_v1.0.pdf
9/2/2022 9:32 AM 552 ._Mariani 2010_v1.0.pdf
9/2/2022 9:40 AM 552 ._Mariani 2011_v1.0.pdf
9/2/2022 9:32 AM 552 ._Mariani G et al.： Thromb Haemost 109(2)： 238-247, 2013_v1.0.pdf
9/2/2022 9:41 AM 552 ._Mavrides E, et al. 2016 Prevention and Management of Postpartum_v1.0.pdf
9/2/2022 9:43 AM 552 ._Mehta 2004_v1.0.pdf
9/2/2022 9:42 AM 552 ._Michelet D et al. 2015 Emergency hysterectomy for life-threateni_v1.0.pdf
9/2/2022 9:28 AM 552 ._Monroe DM et al., Blood Coagul Fibrinolysis, 9(suppl 1)： S15-S20_v1.0.pdf
9/2/2022 9:31 AM 552 ._Munn et al, 2016, J Haem Pract_v1.0.pdf
9/2/2022 9:32 AM 552 ._Munn J Haem Pact_2016_v1.0.pdf
9/2/2022 9:41 AM 552 ._Muñoz M et al. 2019 Patient blood management in obstetrics preve_v1.0.pdf
9/2/2022 9:30 AM 552 ._MX19NSVN0001- Ref 042_Watts_2005- use of rFVIIa for emergency fa_v1.0.pdf
9/2/2022 9:30 AM 552 ._MX19NSVN0001- Ref 36a Rodriguez Merchan 2010 84-88 N7- Surgery i_v1.0.pdf
9/2/2022 9:40 AM 552 ._MX19NSVN00020- 13_Santagostino_2015_v1.0.pdf
9/2/2022 9:43 AM 552 ._MX19NSVN00021 Ref 13_Santagostino_2015_v1.0.pdf
9/2/2022 9:30 AM 552 ._MX19NSVN00021 Ref 25_Takedani_2014_v1.0.pdf
9/2/2022 9:32 AM 552 ._MX19NSVN00021 Ref 28_Salaj_2009_v1.0.pdf
9/2/2022 9:30 AM 552 ._MX19NSVN00021 Ref 36_Laurian_2007_v1.0.pdf
9/2/2022 9:30 AM 552 ._MX19NSVN00021 Ref 39_Banov_2014_v1.0.pdf
9/2/2022 9:30 AM 552 ._MX19NSVN00021 Ref 41_Aouba_2010_v2.0.pdf
9/2/2022 9:30 AM 552 ._MX19NSVN00021 Ref 46_Mehta_2004_v1.0.pdf
9/2/2022 9:28 AM 552 ._MX19NSVN00028- 25. Monroe 1997_v1.0.pdf
9/2/2022 9:28 AM 552 ._MX19NSVN00028- 6. Darby 2004_v1.0.pdf
9/2/2022 9:31 AM 552 ._MX20NSVN00008 17. Sumner Haemophilia 2007_v1.0.pdf
9/2/2022 9:39 AM 552 ._Neufeld EJ et al. 2018 Haemophilia Recombinant activated factor_v2.0.pdf
9/2/2022 9:29 AM 552 ._Neufeld EJ et al.： Blood Rev 29（S1）：S34-S41, 2015_v1.0.pdf
9/2/2022 9:29 AM 552 ._Neufeld, Pediatr Blood Cancer 2013; 60 1178-1183_v1.0.pdf
9/2/2022 9:31 AM 552 ._Neufeld_et al, 2018, Haemophilia_v2.0.pdf
9/2/2022 9:39 AM 552 ._Neufeld_Haemophilia_2018_v1.0.pdf
9/2/2022 9:28 AM 552 ._NHF - MASAC Guidelines, Dec 6, 2018_v1.0.pdf
9/2/2022 9:30 AM 552 ._NovoSeven® in the treatment of acqui·red hemophilia A results fr_v1.0.pdf
9/2/2022 9:28 AM 552 ._NovoSeven® Summary of Product Characteristics Nov 2020_v2.0.pdf
9/2/2022 9:31 AM 552 ._NovoSeven® Summary of Product Characteristics._v1.0.pdf
9/2/2022 9:32 AM 552 ._Nurden et al, 2012, Expert Rev Hematol_v1.0.pdf
9/2/2022 9:30 AM 552 ._OBIZUR Summary of Product Characteristics November 2020_v3.0.pdf
9/2/2022 9:30 AM 552 ._Odeyemi IA, Danø AM. Curr Med Res Opin 2009; 25(1) 239-250_v1.0.pdf
9/2/2022 9:31 AM 552 ._Odeyemi IAO Odeyemi et al. Value Health. 2008;11(6)A633._v1.0.pdf
9/2/2022 9:29 AM 552 ._Odeyemi_2002_51-64_v1.0.pdf
9/2/2022 9:43 AM 552 ._Odeyemi_2008_v1.0.pdf
9/2/2022 9:28 AM 552 ._Oldenburg J et al. 2017 (HAVEN 1)_v1.0.pdf
9/2/2022 9:29 AM 552 ._Ozelo_2007_v1.0.pdf
9/2/2022 9:29 AM 552 ._Parameswaran R et al.Haemophilia 2005; 11 100-106_v1.0.pdf
9/2/2022 9:30 AM 552 ._Pardos-Gea 2018_v1.0.pdf
9/2/2022 9:30 AM 552 ._Polyanskaya T et al.： Haemophilia 18（6）： 997-1002, 2012_v1.0.pdf
9/2/2022 9:31 AM 552 ._Poon MC et al, 2015 The international, prospective Glanzmann Thr_v1.0.pdf
9/2/2022 9:32 AM 552 ._Poon MC, 2007, Vasc Health & Risk Man_v1.0.pdf
9/2/2022 9:40 AM 552 ._Poon, Haematologica. 2015;100(8)1038-44_v1.0.pdf
9/2/2022 9:29 AM 552 ._Pruthi et. al.Thrombosis and Haemostasis 2007; 98 726-732_v1.0.pdf
9/2/2022 9:29 AM 552 ._Putnam_2005_v1.0.pdf
9/2/2022 9:30 AM 552 ._Rajic_2009_v2.0.pdf
9/2/2022 9:42 AM 552 ._Ramler P et al. 2017 Incidence, management and outcome ofwomen_v1.0.pdf
9/2/2022 9:40 AM 552 ._Ref 15 - Amano Haemophilia 2017_v1.0.pdf
9/2/2022 9:33 AM 552 ._Ref 18 - Borel-Derlon ACQUI 7 WFH 2016_v1.0.pdf
9/2/2022 9:30 AM 552 ._Ref 9 - Kruse-Jarres_et_al-2017-American_Journal_of_Hematology_v1.0.pdf
9/2/2022 9:40 AM 552 ._Rodriguez-Merchan E et al 2004 Elective Orthopedic Surgery for H_v1.0.pdf
9/2/2022 9:30 AM 552 ._Rodriguez-Merchan EC et al.： Semin Hematol 41（S1）：109-116, 2004_v1.0.pdf
9/2/2022 9:32 AM 552 ._Salaj et al, Haemophilia 2009; 15 752-59_v1.0.pdf
9/2/2022 9:29 AM 552 ._Salaj et. al. Thrombosis Research 2012; 129 e233-37_v1.0.pdf
9/2/2022 9:32 AM 552 ._Salaj_2009_v1.0.pdf
9/2/2022 9:32 AM 552 ._Santagostino E et al.： Blood Rev 29(S1)： S9-S18, 2015_v1.0.pdf
9/2/2022 9:29 AM 552 ._Santagostino E et al.：Thromb Haemost 4(2)：367-371, 2006_v1.0.pdf
9/2/2022 9:29 AM 552 ._Shapiro AD et al.：Thromb Haemost 80（5）： 773-778, 1998_v1.0.pdf
9/2/2022 9:30 AM 552 ._Shibeko 2014_v1.0.pdf
9/2/2022 9:42 AM 552 ._Sihler C et al. 2010 Complications of Massive Transfusion_v1.0.pdf
9/2/2022 9:43 AM 552 ._SmPC EN NovoSeven 2022-05_v2.0.pdf
9/2/2022 9:32 AM 552 ._Solh et al, 2015, Blood Med_v1.0.pdf
9/2/2022 9:40 AM 552 ._Srivastava A et al, 2013, Haemphilia_v1.0.pdf
9/2/2022 9:33 AM 552 ._Srivastava WFH_2012_Guidelines for the management of haemophilia_v1.0.pdf
9/2/2022 9:29 AM 552 ._Steen_2008_v1.0.pdf
9/2/2022 9:30 AM 552 ._Summary Basis for Regulatory Action - SevenFact 2019_v1.0.pdf
9/2/2022 9:40 AM 552 ._Sun et al 2019 British Journal of Haemotology_v1.0.pdf
9/2/2022 9:30 AM 552 ._Takedani H et al.： Haemophilia 16（2）：290-295, 2010_v1.0.pdf
9/2/2022 9:40 AM 552 ._Takedani_2010_v2.0.pdf
9/2/2022 9:42 AM 552 ._Taylor C et al. 2008 Immunological complications of blood transf_v1.0.pdf
9/2/2022 9:32 AM 552 ._The incidence of factor VIII and factor IX inhibitors in the hem_v1.0.pdf
9/2/2022 9:28 AM 552 ._The need for speed in the management of haemophilia patients wit_v1.0.pdf
9/2/2022 9:42 AM 552 ._Thurn L et al. 2018 Postpartum blood transfusion and hemorrhage_v1.0.pdf
9/2/2022 9:31 AM 552 ._Tiede A et al 2015 The use of recombinant activated factor VII i_v1.0.pdf
9/2/2022 9:31 AM 552 ._Tiede A et al.：Ann Hematol 97（10）：1889-1901, 2018_v1.0.pdf
9/2/2022 9:33 AM 552 ._Tiede A et al.：Semin Thromb Hemost 40：803-811, 2014_v1.0.pdf
9/2/2022 9:39 AM 552 ._Tiede, A. et al 2015 Management of acquired haemophilia_v2.0.pdf
9/2/2022 9:40 AM 552 ._Valentino LA et al 2011 Surgical Experience with rFVIIa (NovoSev_v1.0.pdf
9/2/2022 9:30 AM 552 ._Valentino LA et al.： Haemophilia 17（4）： 579-589, 2011_v1.0.pdf
9/2/2022 9:31 AM 552 ._Vintimilla M et al.：Arthritis Care Res 62（7）：1047-50, 2010_v1.0.pdf
9/2/2022 9:40 AM 552 ._Wallach JB 2007 Interpretation of diagnostic tests_v1.0.pdf
9/2/2022 9:31 AM 552 ._Wallach JB. Interpretation of Diagnostic Tests. 8th ed. Philadel_v1.0.pdf
9/2/2022 9:30 AM 552 ._Wang 2017_v1.0.pdf
9/2/2022 9:32 AM 552 ._Weeterings, 2008, Blood_v1.0.pdf
9/2/2022 9:28 AM 552 ._World Federation of Hemophilia (WFH) Guidelines Guidelines for t_v1.0.pdf
9/2/2022 9:43 AM 552 ._World Hemophilia Federation (WFH) Guidelines Guidelines for the_v1.0.pdf
9/2/2022 9:29 AM 552 ._Young et al, Haemophilia 2008; Slide 08, 09 & 10 ref 1 287-294_v1.0.pdf
9/2/2022 9:32 AM 552 ._Young G et al.： Haemophilia 14(2)： 287-294, 2008_v1.0.pdf